A phase III open-label study of nivolumab (anti-PD-1; BMS-936558; ONO-4538) versus investigator's choice in advanced melanoma patients progressing post anti-CTLA-4 therapy / Ascierto, P. - In: JOURNAL OF CLINICAL ONCOLOGY. - ISSN 0732-183X. - 31:15(2013).

A phase III open-label study of nivolumab (anti-PD-1; BMS-936558; ONO-4538) versus investigator's choice in advanced melanoma patients progressing post anti-CTLA-4 therapy

Ascierto P
2013

2013
A phase III open-label study of nivolumab (anti-PD-1; BMS-936558; ONO-4538) versus investigator's choice in advanced melanoma patients progressing post anti-CTLA-4 therapy / Ascierto, P. - In: JOURNAL OF CLINICAL ONCOLOGY. - ISSN 0732-183X. - 31:15(2013).
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11588/1014086
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact